Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
arketamine hydrochloride
- Development stage
- Unknown
- Lead developer
- Hansoh Pharmaceutical Group
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
Arketamine hydrochloride (HS-10519) is the (R)-enantiomer of the racemic anesthetic ketamine, currently under development as a rapid-acting antidepressant. Unlike esketamine (the S-enantiomer), which is a potent N-methyl-D-aspartate (NMDA) receptor antagonist, arketamine exhibits lower affinity for the NMDA receptor but has shown potent and long-lasting antidepressant-like effects in preclinical models, potentially with a superior safety profile regarding dissociative and psychotomimetic side effects. Its mechanism of action is thought to involve the activation of α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptors and the brain-derived neurotrophic factor (BDNF)-mTOR signaling pathway. HS-10519 is specifically being investigated for major depressive disorder (MDD) in patients with acute suicidal ideation or behavior.
- Other names
- r-ketamine hydrochloride(R)-ketamine hydrochloridearketamine
02
Targets
NMDAR (Glutamate receptor ionotropic, NMDA)NTRK2 (Tropomyosin-related kinase receptor type B)DRD2 (Dopamine D2 Receptor)
Beyond the preview
Go deeper on arketamine hydrochloride.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on arketamine hydrochloride.